摘要
目的：评价丹红注射液治疗分支动脉粥样硬化病脑梗死的有效性及安全性。方法：选择我院2013年6月至2015年5月收治的86例急性脑梗死患者,男49例,女37例,年龄39~82岁,随机分为治疗组和对照组。2组患者均常规给予口服阿司匹林、氯吡格雷和瑞舒伐他汀,静脉滴注依达拉奉,治疗组加用丹红注射液30 ml/d静脉滴注,日1次,连用14 d。2组于治疗前及治疗后第14天,进行神经功能缺损程度评分（NIHSS）及对比总体有效率。结果：治疗后第14天,治疗组神经功能恢复优于对照组,NIHSS评分比较差异有统计学意义（P〈0.05）。治疗组总有效率高于对照组。结论：丹红注射液能显著改善分支动脉粥样硬化病脑梗死患者的预后,提高总体有效率,安全性好。
Objective： To test efficacy and safety of Dan Hong injection in the treatment of cerebral infarction caused by branch atheromatous disease. Methods： A total of 86 cases of acute cerebral infarction in our hospital from Jun 2013 to May 2015,including49 males and 37 females,aged from 39 to 82 years old,were randomly divided into treatment group and control group. All patients were given oral aspirin,clopidogrel and rosuvastatin,intravenous infusion of Edaravone. The treatment group was treated with Dan Hong injection 30 ml / d intravenous drip,once a day,once every 14 days. Before treatment,14 days after treatment,neurological deficit score（ NIHSS） and the overall efficiency was compared in 2 groups. Results： Fourteenth days after treatment in the treatment group,neural function recovery was significantly better than that in the control group,the NIHSS score was significantly different（ P〈0. 05）. The total effective rate in the treatment group was significantly higher than that in the control group at fourteenth days（ P〈0. 05）. Conclusion： Dan Hong injection can significantly improve the prognosis of the patients with cerebral infarction caused by branch atheromatous disease,improve overall efficiency and the drug safety.
出处
《沈阳医学院学报》
2016年第1期18-20,共3页
Journal of Shenyang Medical College
关键词
分支动脉粥样硬化病
脑梗死
丹红注射液
豆纹动脉
脑桥旁正中动脉
branch atheromatous disease
cerebral infarction
Dan Hong injection
lenticulostriate artery
paramedian pontine artery
